Defence Therapeutics Inc Class A · CSE:DTC
Defence Therapeutics Inc Class A — Investor Presentation (September 2026)
19 slides from Defence Therapeutics Inc Class A's investor presentation, September 2026
Slide 1: Defence Therapeutics: Unlocking the Power of Cancer Drugs
INVESTOR PRESENTATION · SEPTEMBER 2026 Defence Therapeutics Unlocking the Power of Cancer Drugs Dr. Amie Phinney, PhD, MBA · President & Chief Executive Officer CSE: DTC · OTCQB: DTCFF · FSE: DTC · Montreal, Canada
Slide 2: Forward-Looking Statements
IMPORTANT NOTICE Forward-Looking Statements This presentation contains forward-looking information within the meaning of applicable Canadian securities laws, including statements about Defence Therapeutics Inc.’s (“Defence” or the “Company”) business and corporate strategy, its Accum®, ADC, radiothe
Slide 3: Defence Therapeutics at a Glance
COMPANY SNAPSHOT Defence Therapeutics at a Glance LISTINGS CSE: DTC · OTCQB: DTCFF · FSE: DTC MARKET SNAPSHOT LOCATIONS Montreal, Quebec, Canada $37.3M CAD Market capitalization (approx., Sept 2026) Hamilton, Ontario, Canada FOCUS Precision oncology via The Accum® Platform 75.8M Common shares outsta
Slide 4: Powerful Oncology Therapies. Persistent Biological Barriers.
THE PROBLEM Powerful Oncology Therapies. Persistent Biological Barriers. Checkpoint Inhibitors | Targeted Radiopharmaceuticals | Antibody -Drug Conjugates POWERFUL THERAPIES BIOLOGICAL BARRIERS Checkpoint inhibitors (CPIs), antibody-drug conjugates CPIs — insufficient immune recognition limits (ADCs
Slide 5: The Accum Platform: Unlocking the full potential of oncology's most powerful therapies
THE SOLUTION The Accum® Platform: Unlocking the full potential of oncology’s most powerful therapies The Accum® Platform combines two nature-inspired mechanisms—endosomal escape and nuclear localization—to overcome intracellular barriers that can limit therapeutic performance. BROADLY APPLICABLE Imm
Slide 6: One Platform. Multiple Paths to Value. Execution Underway.
WHY DEFENCE THERAPUTICS, WHY NOW One Platform. Multiple Paths to Value. Execution Underway. Differentiated Oncology Platform High-Value Commercial Opportunities • Accum® is designed to enhance established and next-generation • AccuTOX® — clinical-stage immuno-oncology opportunity cancer therapeutics
Slide 7: One Platform. Multiple Paths to Value.
MULTIPLE PATHS TO VALUE One Platform. Multiple Paths to Value. Focused investment across three pillars where Accum® can create differentiated clinical and commercial value 01 Positioning AccuTOX® for Clinical Development and Value Creation. 02 Building a Proprietary Pipeline of Accum®-Enabled Radiop
Slide 8: Making tumours more visible to the immune system
PILLAR 1 OF 3 Making tumours more visible to the immune system AccuTOX® combines direct tumour killing with enhanced antigen presentation to amplify checkpoint inhibitor activity ~2x ~85% 100% Increase in MHC-I antigen presentation on Slower tumour growth with combination Survival across all treated
Slide 9: Positioning AccuTOX for Clinical Development and Value Creation
PILLAR 1 OF 3 Positioning AccuTOX® for Clinical Development and Value Creation Clinical-stage asset with regulatory clearance and trial infrastructure in place OUR MOST CLINICALLY ADVANCED ASSET MARKET OPPORTUNITY Regulatory path established Health Canada and FDA clearance to initiate Phase I develo
Slide 10: Building a Proprietary Pipeline of Accum-Enabled Radiopharmaceuticals
PILLAR 2 OF 3 Building a Proprietary Pipeline of Accum®-Enabled Radiopharmaceuticals New Leadership Targeted radiopharmaceuticals are emerging as an important new class of Dr. Ryan Simms cancer therapy but can be constrained by limited tumour uptake and COO & Head of Radiopharmaceutical Programs ret
Slide 11: From Platform Validation to Proprietary Radiopharmaceutical Asset
PILLAR 2 OF 3 From Platform Validation to Proprietary Radiopharmaceutical Asset MA R K E T VA LID A T E D W IT H R E C E N T M&A D E A LS 2026-2027 PRIORITIES 1. Generate proof-of-concept data demonstrating where Accum® Lantheus × Evergreen Theragnostics ~$1.0B PET diagnostic OCTEVY; preclinical and
Slide 12: Accum Enhances HER2 ADCs Across Multiple Breast Cancer Models
PILLAR 3 OF 3 Accum® Enhances HER2 ADCs Across Multiple Breast Cancer Models ~20x 2 Marketed ADCs Difficult-to-treat models Activity demonstrated in resistant and lower- Greater anti-tumour efficacy in vivo models Enhancement demonstrated with both T-DM1 with Accum®-T-DM1® vs. T-DM1 alone and T-Dxd
Slide 13: Drive Accum adoption through partnerships & scalable licensing model
PILLAR 3 OF 3 Drive Accum® adoption through partnerships & scalable licensing model We enable, not compete MARKET VALIDATED WITH RECENT LICENSING DEALS Our objective is not to develop competing ADCs, but to enable ADC developers — engaging companies whose assets could benefit from Astellas × Evopoin
Slide 14: Partnership-Led Licensing Model
BUSINESS MODEL Partnership-Led Licensing Model 1 2 3 4 Partner Brings › Defence Applies › Licensing Revenue › Reinvest in the the Asset Accum® Pipeline An ADC or biologic developer Accum® is evaluated to enhance Defence earns upfront Proceeds fund AccuTOX®, contributes a clinical or intracellular de
Slide 15: An Experienced Team Leading the Next Stage
LEADERSHIP An Experienced Team Leading the Next Stage Dr. Amie Phinney, PhD, MBA Sébastien Plouffe President & Chief Executive Officer, Board Director Executive Chairman & Founder, Board Director 20+ years in international biotech leadership, including Founded Defence and built the Accum® platform a
Slide 16: An Expanded Board Adds Deep Scientific Credibility
GOVERNANCE An Expanded Board Adds Deep Scientific Credibility New! Dr. John Lambert Board Director — ADC Pioneer Dr. Philippe Lefrançois Dr. Svetlana Selivanova 40+ years in ADC science. Former Chief Scientific Officer and EVP Research at Board Director — Clinical Science Board Director — Radiothera
Slide 17: What to Expect Over the Next Twelve Months
ROADMAP What to Expect Over the Next Twelve Months Defined milestones across each strategic pillar AccuTOX® Radiotherapeutics ADC Collaborations Define the highest-value Generate foundational Accum® data Expand Accum®-ADC profiling commercialization path with partners Update clinical development pla
Slide 18: Investment Highlights
SUMMARY Investment Highlights Differentiated, IP-protected platform Capital-efficient commercialization strategy 8 U.S. granted patents and preclinical data demonstrating Partner-led ADC business model designed to generate near-term enhancement of multiple biologic drug categories revenue, with mile
Slide 19: Thank You for Your Continued Confidence.
LOOKING AHEAD Thank You for Your Continued Confidence. “With a differentiated technology platform and a focused strategy, Defence is well positioned to translate years of scientific innovation into programs and partnerships that can define our future.” — Dr. Amie Phinney, PhD, MBA, President & Chief
Defence Therapeutics — Investor Presentation (September 2026) on 6ix